Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma

Area of Science:

• Oncology
• Pharmacology
• Medical Treatment

Background:

• Drug resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) presents a challenge in advanced non-small cell lung cancer (NSCLC).
• Osimertinib, a third-generation EGFR-TKI, is being investigated for its efficacy and safety in NSCLC patients with resistance to earlier EGFR-TKIs, particularly in lung adenocarcinoma.
• The current understanding of osimertinib's effectiveness in this specific patient group remains limited.

Purpose of the Study:

• To evaluate the efficacy of osimertinib in treating patients with advanced lung adenocarcinoma.
• To assess the safety and adverse reactions associated with osimertinib treatment in this patient population.

Main Methods:

• A cohort of 90 patients with advanced (stage IV) lung adenocarcinoma was studied retrospectively.
• Patients had progressed on first-line EGFR-TKI treatment (94.4%), with many receiving third-line or later treatment (43.3%).
• Efficacy and adverse events of osimertinib were observed and recorded.

Main Results:

• An objective response rate (ORR) of 63.3% and a disease control rate (DCR) of 93.3% were achieved.
• Median progression-free survival (mPFS) was 10.41 months, and median overall survival (mOS) was 31.37 months.
• The incidence of severe adverse events (grade 3+) was low at 7.78%, with diarrhea and rash being the most common, and symptoms were manageable with treatment.

Conclusions:

• Osimertinib demonstrates significant efficacy in treating advanced lung adenocarcinoma.
• The drug is well-tolerated, with a low incidence of severe adverse reactions.
• Osimertinib represents a valuable therapeutic option for advanced lung adenocarcinoma patients, especially those with prior EGFR-TKI resistance.